GlaxoSmithKline’s new chief executive said on Tuesday that the British drugmaker would have a look at Pfizer Inc’s consumer products business, but would not overpay for the asset.
Pfizer, the largest U.S. drugmaker, said last year it was considering strategic alternatives, including a sale or spinoff, of the consumer business, which had sales of about $3.4 billion in 2016 and could cost more than $15 billion to acquire.
“At this stage it would be weird if we didn’t look at it,” GSK Chief Executive Emma Walmsley said, responding to questions at the JP Morgan Healthcare Conference in San Francisco.
But she said it is only a look and very early, adding, “we don’t need it and we won’t overpay for it.”
Despite her consumer products background, Walmsley repeatedly said that the company’s pharmaceuticals business and pharma research and development is GSK’s top priority.
However, Walmsley said GSK has a good track record of integrating large acquisitions and that it’s consumer business does have room to grow.
Pfizer’s consumer portfolio includes well-known brands such as Advil, Chapstick lip balm and Centrum vitamins.
Walmsley said there are a very small number of assets that would be completely complementary to GSK’s existing consumer business, “and this may be one of them.”
“If we did it, it is cash generating,” she said.
By Bill Berkrot
Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.
Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.
Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.